Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection

Launched by SHICAI YE · Jul 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a new medication called vonorasan, combined with aluminum phosphate gel, for treating ulcers that can develop after a specific type of surgery called endoscopic submucosal dissection (ESD). The trial aims to see if this combination works better than a standard treatment, which is esomeprazole combined with aluminum phosphate gel. Researchers want to find out how well the treatment heals these ulcers and if there are any problems or side effects for people taking the medication.

To be eligible for the trial, participants should be between 18 and 70 years old and have undergone ESD surgery with postoperative ulcers that are 3 centimeters or smaller. They should not have severe health issues that could affect the study's results or need to take certain medications that might interfere with the trial. Those who join will receive either the new treatment or the standard treatment for several weeks, and their symptoms and ulcer healing will be monitored. This trial is not yet recruiting participants, but it offers a chance to receive new treatment options for managing ulcers after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meets surgical indications for ESD
• • Age 18-70 years, regardless of gender
• • Normal coagulation
• • ESD Postoperative ulcers ≤3cm
• • Voluntary participation in the study
• Exclusion Criteria:
• • Patients with severe complications or failure to achieve curative resection after gastric ESD surgery need supplementary surgery
• • Women who are pregnant or breastfeeding, or who may conceive during clinical trials
• • The patient has other serious organic diseases that affect the evaluation of the study, such as severe liver disease, heart disease, renal disease, malignant neoplasm and alcoholism
• • Patients who need to take antiplatelet and NSAIDS drugs for a long period of time
• • Co-administration of unspecified anti-ulcer drugs during the trial period;Allergic reactions to vornoxan, aluminium phosphate gel or esomeprazole
• • Patients with no capacity for autonomous behaviors, unable to correctly express their main complaint, such as those with mental illness, severe neurosis, and unable to cooperate with this experiment
• • ESD Postoperative ulcers \>3cm